Effect of dna methylation on inhibitor development in hemophilia a patients treated with fviii concentrates

Introduction Haemophilia A (HA) is a hereditary X-linked haemorrhagic bleeding disorder. Following the treatment with exogenous FVIII, roughly one-third of patients with severe HA develop anti-FVIII antibodies (inhibitors), that renders treatment ineffective. Our aim is to detect CpG sites that are differentially methylated (DMCs) in peripheral blood mononuclear cells (PBMCs) of patients with and without an inhibitor, using a genome-wide approach, to better understand the biological pathways that leads to inhibitor development.